바이오인

R&D is the lifeblood of the biopharmaceutical industry, the ultimate source of the economic value that the industry creates.  Little wonder, then, that the continuint evidence of a major decline in R&D productivity has generated a sense of crisis not just in R&D circles but in the industry as a whole.